Tesamorelin Dosing Protocol: GHRH Analog Research

Also known as: Egrifta

hormonal

Research Reference Only

This information is for educational purposes only. Tesamorelin is not FDA approved for human use. The protocols listed are summaries of published research studies and do not constitute medical advice. Always consult a licensed healthcare provider.

Overview

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates endogenous growth hormone production. It is FDA-approved for HIV-associated lipodystrophy and has been studied for reducing visceral adipose tissue.

Mechanisms of Action

Stimulates pituitary release of growth hormone

Increases IGF-1 levels

Reduces visceral adipose tissue

Preserves subcutaneous fat

Improves lipid profiles

Research Protocols

The following protocols are summaries of published research studies. They are presented for educational purposes only and do not constitute medical advice.

Protocol Name	Source	Dose	Frequency	Duration	Route	Evidence	Link
HIV Lipodystrophy Protocol	published study	2 mg	Daily	26 weeks	Subcutaneous	human

Important Warnings

Safety Considerations

May increase risk of diabetes
Fluid retention possible
Carpal tunnel syndrome reported
Requires daily injections